No polarization of type 1 or type 2 precursor dendritic cells in peripheral blood stem cell collections of non-Hodgkin's lymphoma patients mobilized with cyclophosphamide plus G-CSF, GM-CSF, or GM-CSF followed by G-CSF

被引:17
|
作者
Gazitt, Y [1 ]
Akay, C [1 ]
Thomas, C [1 ]
机构
[1] Univ Texas, Hlth Sci Ctr, San Antonio, TX 78284 USA
关键词
D O I
10.1089/scd.2006.15.269
中图分类号
Q813 [细胞工程];
学科分类号
摘要
Dendritic cells (DCs) are the most efficient antigen-presenting cells and play a role in immune reconstitution after autologous transplantation. Recent reports suggest that mobilization with granulocyte colony-stimulating factor (G-CSF) containing regimens polarizes DCs into pDC2, which could potentially result with increased Th2 response and decreased graft-versus-host disease (GVHD) in allogeneic transplantation and with decreased cytotoxic Th1 response and graft versus tumor effect, which in autologous transplantation could translate into increased relapse rate. Previously, we have shown that non-Hodgkin's lymphoma (NHL) patients receiving cyclophosphamide (CTX) plus granulocyte-macrophage (GM)-CSF, G-CSF or GM-CSF followed by G-CSF for stem cell collection, mobilize up to five-fold more mature CD80(+) DCs compared to CTX plus G-CSF mobilized patients. Here, we analyzed samples from the same study for the number of pDC1 and pDC2 subsets in blood and apheresis products obtained from these patients. Samples from 29 patients were collected. Patients mobilized with CTX plus G-CSF collected a mean of 1.2 +/- 0.4 x 10(6) pDC1/kg per day and 2.2 +/- 1 x 10(6) pDC2/kg per day, whereas patients mobilized with CTX plus GM-CSF collected a mean of 1.1 +/- 0.5 x 10(6) pDC1 and 1.5 +/- 0.9 x 10(6) pDC2/kg per day. Patients mobilized with CTX plus GM-CSF followed by G-CSF collected 2.5 +/- 1.1 x 10(6) pDC1 and 2 +/- 0.5 x 10(6) pDC2/kg per day, with significantly higher levels of pDC1 +/- pDC2 cells. No significant difference was observed in pDC1/pDC2 ratio between the three mobilization arms. Patients mobilized with the GM-CSF-containing regimen had a higher probability for survival compared to patients receiving G-CSF alone (median of 55 months vs. 15 months; p = 0.02). These results support the hypothesis that higher levels of DCs in the graft might be associated with prolonged survival of autotransplanted NHL patients. Further similar studies are merited in a larger population of NHL patients.
引用
收藏
页码:269 / 277
页数:9
相关论文
共 50 条
  • [41] Results of stem cell mobilization and subsequent engraftment after G-CSF plus GM-CSF in children with leukemia and solid tumors
    Anak, S
    Bilgen, H
    Ozgenc, S
    Can, E
    Yalman, N
    Gedikoglu, G
    BONE MARROW TRANSPLANTATION, 2002, 29 : S209 - S209
  • [42] Mobilization of dendritic cells from patients with breast cancer into peripheral blood stem cell leukapheresis samples using Flt-3-Ligand and G-CSF or GM-CSF
    Gasparetto, C
    Gasparetto, M
    Morse, M
    Rooney, B
    Vredenburgh, JJ
    Long, GD
    Rizzieri, DA
    Loftis, J
    Chao, NJ
    Smith, C
    CYTOKINE, 2002, 18 (01) : 8 - 19
  • [43] ESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma: comparison with high-dose cyclophosphamide plus G-CSF
    J-L Lee
    S Kim
    S W Kim
    E-K Kim
    S-B Kim
    Y-K Kang
    J Lee
    M W Kim
    C J Park
    H-S Chi
    J Huh
    S-H Kim
    C Suh
    Bone Marrow Transplantation, 2005, 35 : 449 - 454
  • [44] ESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma: comparison with high-dose cyclophosphamide plus G-CSF
    Lee, JL
    Kim, S
    Kim, SW
    Kim, EK
    Kim, SB
    Kang, YK
    Lee, J
    Kim, MW
    Park, CJ
    Chi, HS
    Huh, J
    Kim, SH
    Suh, C
    BONE MARROW TRANSPLANTATION, 2005, 35 (05) : 449 - 454
  • [45] Phenotypic and functional characterization of peripheral blood stem cells mobilized either with G-CSF or G-CSF plus stem cell factor in myeloma patients.
    Bohbot, A
    Maloisel, F
    Allam, A
    Karcher, V
    Faradji, A
    Oberling, F
    Lioure, B
    BLOOD, 1997, 90 (10) : 4200 - 4200
  • [46] High dose cyclophosphamide plus GM-CSF versus G-CSF alone to mobilize PBSCs for autologous transplantation in multiple myeloma
    Alegre, A
    Tomas, LF
    Escudero, A
    GilFernandez, JL
    Arranz, R
    Granda, A
    LopezPascual, K
    Lopez, JL
    Pinilla, I
    FernandezRanada, JM
    BLOOD, 1995, 86 (10) : 3733 - 3733
  • [47] Comparison of the efficacy and tolerance of interleukin-3, G-CSF and GM-CSF following aggressive chemotherapy in patients with non-Hodgkin's lymphoma - A randomized study.
    Brown, PN
    Hovgaard, D
    Remes, K
    Holm, M
    Teerenhovi, L
    Elonen, E
    Nissen, NI
    BLOOD, 1996, 88 (10) : 2264 - 2264
  • [48] Recombinant human GM-CSF or recombinant human G-CSF for the mobilization of peripheral blood stem cells - Results of a prospectve randomized study.
    Hohaus, S
    Martin, H
    Goldschmidt, H
    Haus, U
    Farber, L
    Burger, KJ
    Hoelzer, D
    Haas, R
    BLOOD, 1997, 90 (10) : 432 - 432
  • [49] Comparison of four cytokine regimens for mobilization of peripheral blood stem cells: IL-3 alone and combined with GM-CSF or G-CSF
    Rosenfeld, CS
    Bolwell, B
    LeFever, A
    Taylor, R
    List, A
    Fay, J
    Collins, R
    Andrews, F
    Pallansch, P
    Schuster, MW
    Resta, D
    Levitt, D
    Nemunaitis, J
    BONE MARROW TRANSPLANTATION, 1996, 17 (02) : 179 - 183
  • [50] VASCULAR ENDOTHELIAL-CELLS AND GRANULOPOIESIS - INTERLEUKIN-1 STIMULATES RELEASE OF G-CSF AND GM-CSF
    ZSEBO, KM
    YUSCHENKOFF, VN
    SCHIFFER, S
    CHANG, D
    MCCALL, E
    DINARELLO, CA
    BROWN, MA
    ALTROCK, B
    BAGBY, GC
    BLOOD, 1988, 71 (01) : 99 - 103